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Abstract: On April 7, 2017, TEDD (Tissue Engineering for Drug
Development and Substance Testing) and the Animal Research
Foundation joined forces at ZHAW Waedenswil to present their
latest scientific results in the domain of the 3Rs of biomedical
research: how to Refine, Reduce and Replace animal testing with
alternative approaches.
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One promising avenue towards animal-free research is
the use of sophisticated in vitro cell and tissue models using
human cells. The use of animal products is still widespread in
cell cultivation, namely Fetal Calf Serum (FCS). FCS or FBS
(Fetal Bovine Serum) – as it is also called today – is the blood
fraction remaining after the coagulation of blood, followed by
centrifugation to remove any remaining red blood cells. Today it
is an essential admixture to animal and human cell culture media
as it has a very low level of antibodies and contains growth factors,
allowing for versatility in different cell culture applications. But
Dr. Gerhard Gstraunthaler, from the Division of Physiology at
Medical University of Innsbruck, lists a series of disadvantages.
Quo vadis FBS?
“These include unknown composition, seasonal and
geographical lot-to-lot variability, safety concerns in terms of
endotoxins, mycoplasma, viral contaminants or prion proteins
and unpredictable shortages in global supply”, says the professor.
“Most serious are the ethical concerns about animal welfare and
the collection of blood from unborn bovine fetuses. This is a
cause of concern, as recent figures estimate that approx. 800,000
liters of FBS are produced annually worldwide, corresponding
TEDD and Animalfree Research discuss the challenges of serum-free
cell culture on the occasion of the TEDD & 3R Workshop organized at
the ZHAW Waedenswil on 7 April 2017. © ZHAW Waedenswil.
to the harvesting of 2,000,000 bovine fetuses, and the numbers
continue to grow.” The fact remains that the global supply of FBS
is still a dark market that is only loosely regulated: exact numbers
for both global production of FBS and availability, as well as the
worldwide demand are still unknown. This situation could create
opportunities for abuse and fraudulent blending of FBS. “In 1994,
it was reported that approx. 30,000 liters of ‘New Zealand’ serum
were sold worldwide. However, only 15,000 liters of high-quality
FBS were collected annually in New Zealand.”
A solution for the future?
The search for strategies to reduce or replace FBS in cell
culture is experiencing a boom. The recently developed activated
human donor platelets (human platelet lysates, hPL) appear very
promising. “The rationale behind the use of hPL is the clotting
process itself, which includes the activation of platelets and the
exocytic release of α-granule factors”, explains the researcher.
“Platelet α-granules contain an array of growth factors required
for wound healing and tissue regeneration, but they have also
been identified as being essential for cell attachment, growth and
proliferation in vitro.” The conditions look good: “hPL are
obtained from expired human donor platelets, a recognized,
ethically approved, safe and clinically tested, high-quality
product.With hPL, bulk platelet growth factors are added to basal
culture media, providing a human-based, xeno-free culture
system.”
As Gerhard Gstraunthaler
and his team proved, the
cocktail of platelet factors
supported growth and
proliferation of human
and animal cell lines. The
addition of hPL to quiescent
culture stimulated the
ERK1/2 MAPK signaling
pathway, strongly indicating
the mitogenic potential of
platelet α-granule growth
factors. “We showed that
adipose-derived mesenchy-
mal stem cells (ADSC)
could be expanded under
hPL-supplemented culture
conditions, and that the cells
maintained their undifferen-
tiatedoligopotentphenotype,”
explains the Austrian expert.
“In addition, ADSC under
hPL were able to retain their
full mesodermal differentiation potential towards adipogenic,
osteogenic and chondrogenic phenotypes. That means hPL is the
most valuable replacement of FBS in the culture of animal and
human cells, including adult stem cells.”
‘Zell- und Gewebekultur’
Prof. Dr. Gerhard Gstraunthaler
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Professor Gerhard Gstraunthaler
from the University of Innsbruck is
critical as to the widespread use
today of Fetal Bovine Serum and
presents options as alternatives to
FBS. © ZHAW Waedenswil.
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Improving Reproducibility in Science
Scientific progress is assured by trusted discoveries, recalls
Professor Thorsten Buch, Head of the Institute of Laboratory
Animal Science (LTK) at the University of Zurich. As well as
conducting research, every year the LTK introduces hundreds of
Swiss and international scientists to the appropriate methodology
for conducting human and scientifically sound animal
experiments.
To gain confidence in their conclusions, it is important for
them to reproduce experiments. “Most scientific results are not
reproducible,” states the biologist, citing headline news articles
from scientific journals and newspapers. “But reproducibility
enables the scientist to support an experimental hypothesis and to
turn it intoacceptedknowledge.”Scienceworkson theassumption
that what we discover today will also be true tomorrow. It thus
facilitates prediction. “For animal experiments the reproduction
of results has been called into question due to the apparent, or
imagined, lack of translation into clinical – human – application”,
comments Thorsten Buch. “Reproducibility has been associated
with measures of good scientific practice and claims to the effect
that absence of these actions implies absence of reproducibility.”
Such measures usually include standards of statistical and
experimental planning.
But are these measures truly indicators of reproducibility?
Is the sloppy use of such standards the cause of the apparent
reproducibility crisis, or do other factors contribute to the
variability seen in the outcomes of experiments in biomedical
research? What causes of irreproducibility can be avoided,
and what are elementary features when it comes to gathering
The Transgenic Technologies Laboratory at the Institute of Laboratory
Animal Sciences (LTK) gives scientists access to state-of-the-art
technology for their research. Picture: Institute of Laboratory Animal
Sciences LTK
new scientific knowledge? Thorsten Buch suggests ten points
to improve biomedical science – from training through lab
organization to publication standards.At present, science journals
insist that each paper contains a story, and this story should not
be descriptive but should reveal the underlying mechanisms.
“But let’s be realistic: We do not need top-selling stories about
scientific results, but the description of observations – it’s the only
thing that counts!” To support such a shift, the LTK-run animal
welfare website Swiss3Rnetwork has entered into a collaboration
with the new online journal Science Matters, based in Zurich.
Thorsten Buch closes by suggesting that, when working with
animals, researchers should add three more ‘Rs’ to the existing
ones: Respect, Responsibility, Reproducibility.
E-mail: thorsten.buch@uzh.ch
3R – An Important Factor in Pharmaceutical Research
The fact that alternatives to animal testing shouldmore closely
reflect human biology and result in a better prediction of efficacy
and safety of new medicines may explain the appearance of
animal-free research in industrial labs. As Dr. Birgit Ledermann
explains, the implementationof the3Rs inanimal research isahigh
priority for Novartis. Themultinational pharmaceutical company,
where she is responsible for the Novartis 3Rs programme, fully
supports the use of alternatives to animal research wherever
feasible. “Today, the3Rsare increasingly important,with agreater
focus on developing alternatives to animal testing,” says Birgit
Ledermann, who also serves as president of the Swiss Laboratory
Animal Science Association. Since 1987 this organization has
served as an intermediary between animal welfare and research
for the benefit of humans and animals, and is a key partner for
authorities, scientists and public, promoting the 3Rs. “Scientists
at Novartis are urged to search for alternative ways to conduct
studies before undertaking animal research,” she comments. “To
help achieve this aim, Novartis adheres to the principles of the 3Rs.
Their implementation is applicable to a variety of areas, including
the environment, nutrition, health status of the animals, procedural
training, education and, finally, animal experimentation.”
As an example of education and training at Novartis, she
mentions the rabbit silicone ear invented by a Novartis animal
caretaker. This is a patented training device for taking blood and
carrying out intravenous injections in rabbit ear veins and arteries.
In this way it replaces the need to use live animals in initial basic
exercises for trainees in animal experimental techniques.
Novartis adheres to the principles of the 3Rs, implemented in a
variety of areas, including the environment, nutrition, health status
of the animals, procedural training, education and, finally, animal
experimentation. Copyright Novartis.
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international level for components used in the manufacture of
clinical applications. “We invite all Swiss centers in this domain
to support our efforts to build a future platform for cell therapy
and translational medicine in order to produce clinical products
of irreproachable quality with a common commitment.
E-mail: eliane.mueller@dkf.unibe.ch
Let’s Close Ranks!
In bringing together representatives from the cell culture
industry and applied scientists, Professor Michael Raghunath
wants to take a closer look at the possibility of serum-free
cell culture. He has the welfare of animals very much at heart,
as he was for many years a member of the NUS Institutional
Animal Care and Use Committee IACUC, evaluating the work
with animals, monitoring animal welfare at the university and
inspecting animal holding facilities. “If an animal is suffering
stress or pain, this could affect the results of a test,” he states.
“It therefore makes sense that – if a test with animals cannot
be avoided – they must be treated with care and kept in the best
possible conditions. In the case of FBS (Fetal Bovine Serum), for
many decades an invaluable and essential admixture to animal
and human cell culture media, we are entitled to ask whether
this serum is still strictly necessary today, as we know about all
its negative effects.” When in doubt, leave it out? Unfortunately,
it’s not as easy as it looks. “Without serum, cells do not thrive,
so replacement factors must be found that keep the cells going,”
recalls Michael Raghunath. But this will not be easy, as this is
cell type-dependent, and we have over 200 different types of cells
in our body! “Each component has to originate from animal-free
substances, which requires full documentation,” explains the
Head of Cell Biology and Tissue Engineering. But this workshop
has shown us that these problems can only be solved if all partners
join a network that is focused on cooperating and sharing skills,
knowledge and experience. “Wewant to contribute to animal-free
research by developing, implementing and teaching the methods
of stem-cell culture and the realization of relevant, living tissue
models for testing, diagnostics and therapy. Do you want the
same as us? Simply contact us!”
Your contact partner for inquiries:
Prof. Dr. Michael Raghunath
ZHAW Life Sciences and Facility Management
E-mail: michael.raghunath@zhaw.ch
Received: April 24, 2017
A further example of replacement concerns a close col-
laboration between Novartis and the TEDD group at ZHAW
Waedenswil. The aim is to replace animal testing in musculo-
skeletal disease areas such as sarcopenia and cachexia. In col-
laboration with TEDD, Novartis has developed a methodology
for engineering human skeletal muscle and tendon tissues using
3D bioprinting. Since Novartis believes in the future reduction,
refinement and replacement of animal testing, the Basel based
company attaches considerable importance to close cooperation
with the TEDD group in this domain.
E-mail: birgit.ledermann@novartis.com
Call for Swiss Animal-free Translational Medicine
In order to drive forward the process of translational
medicine in Switzerland, the Swiss Institute for Translational and
Entrepreneurial Medicine is being set up on the Campus of the
Insel University Hospital. This Sitem-Insel, which is a not-for-
profit organization, will train specialists in translation, provide
high-tech infrastructure and personnel at the interface between
industry, clinical research and university hospitals, and fast-track
the administrative/regulatory processes from the laboratory
bench to clinical applications or bedside. A strong focus is the
3D co-culture of fibroblasts and keratinocytes at the air–liquid
interface developed by CELLnTEC advanced cell systems AG.
“The unique selling proposition and benefits are fully defined,
animal component-free and higher quality certified products
which are unique in the cell culture market around the world.
They are optimally suited for clinical applications,” explains
Professor Eliane Mueller, Head of Dermatology & Stem Cell
Research at Bern University and Insel University Hospital,
founder and chairperson of CELLnTEC and advisor of Sitem-
Insel for stem cell research. She brings a wealth of knowledge
in dermatology and skin stem cells. “Our innovations comprise
full-thickness skin models with a fully natural dermal matrix that
is secreted completely by the fibroblasts. This is much more in
vivo-like and avoids the use of artificial collagen gels, which are
time-consuming, variable and expensive.” But the country now
needs strict regulatory conditions in relation to providers at the
Full-thickness skin model with a fully natural dermal matrix, produced
with CnT-PR-F and CnT-PR-FTAL media by CELLnTEC, advanced cell
systems AG, Bern. Picture CELLnTEC.
Prof. Eliane Mueller and the ‘driving forces‘ behind the TEDD network:
Dr Ursula Graf-Hausner, Board member, and Prof. Michael Raghunath,
Director (left to right). Picture ZHAW.
